Skip to NavigationSkip to content

News

Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that the therapy met all of its co...
Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 trial of its ovarian cancer drug...
Venclexta has been approved by the FDA in combination with Gazyva for the treatment of chronic lymphocytic leukaemia (CLL) or small lymphocytic...
Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical...
Healthcare conglomerate Johnson & Johnson has said it will be investing €100 million into the expansion of its Vision Care manufacturing...
Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for FDA approval by the US agency’s...
The FDA has approved Bavencio (avelumab) in combination with Inlyta (axitinib) for the treatment of advanced renal cell carcinoma (RCC). The...
NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza.
Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for HIV drugs,...
“In the life sciences industry, we see a shift toward transparency and collaboration,” says Robert Groebel, Vice President of Medical Strategy at...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches